Duncker Streett & Co. Inc. Sells 1,283 Shares of Danaher Co. (NYSE:DHR)

Duncker Streett & Co. Inc. lessened its stake in Danaher Co. (NYSE:DHR) by 2.3% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 54,988 shares of the conglomerate’s stock after selling 1,283 shares during the quarter. Danaher makes up approximately 2.6% of Duncker Streett & Co. Inc.’s investment portfolio, making the stock its 8th largest position. Duncker Streett & Co. Inc.’s holdings in Danaher were worth $13,739,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. IFG Advisory LLC acquired a new position in Danaher during the second quarter worth approximately $316,000. Concurrent Investment Advisors LLC boosted its position in Danaher by 69.6% during the second quarter. Concurrent Investment Advisors LLC now owns 3,679 shares of the conglomerate’s stock worth $919,000 after purchasing an additional 1,510 shares during the period. Private Ocean LLC raised its position in shares of Danaher by 11.3% in the second quarter. Private Ocean LLC now owns 445 shares of the conglomerate’s stock valued at $111,000 after purchasing an additional 45 shares during the period. Legacy Advisors LLC raised its position in shares of Danaher by 15.6% in the second quarter. Legacy Advisors LLC now owns 4,962 shares of the conglomerate’s stock valued at $1,240,000 after purchasing an additional 668 shares during the period. Finally, Rothschild Investment LLC acquired a new stake in shares of Danaher during the 2nd quarter worth about $1,089,000. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by company insiders.

Danaher Price Performance

Shares of NYSE:DHR opened at $269.31 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The firm has a market cap of $194.50 billion, a PE ratio of 45.65, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The firm’s fifty day moving average is $260.05 and its 200-day moving average is $255.19.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the company posted $2.05 EPS. The business’s revenue was down 2.9% on a year-over-year basis. Sell-side analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Leerink Partners increased their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. TD Cowen increased their target price on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Bank of America lifted their price target on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Wells Fargo & Company started coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective on the stock. Finally, Royal Bank of Canada lifted their target price on Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.